Treatment
Treatment literacy materials that cover the basics of hepatitis C treatment, research on efficacy in different key populations, and global treatment uptake.
Materials in this section
HCV and HIV Coinfection: Decreasing Barriers to an HCV Cure With Use of a Simplified Treatment Algorithm
In 2023, the AASLD/IDSA treatment guidelines were updated to include the addition of the simplified algorithm in treatment-naive individuals with HIV/HCV coinfection. More
Hepatitis C Reinfection After DAA Therapy Linked to Substance Use, Comorbid HCC
In a large cohort of U.S. veterans, repeat viremia in adults with HCV who achieve SVR via DAA therapy may be more frequent among younger populations and those with a history of substance use or comorbid HCC. More
Understanding Barriers to Hepatitis C Antiviral Treatment in Low–Middle-Income Countries
Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, analysed and summarized as recommendations for LMICs. More
Subspecialty Physicians’ Perspectives on Barriers and Facilitators of Hepatitis C Treatment: A Qualitative Study
A study examined the perspectives of subspecialist physicians caring for substantial numbers of patients with HCV to better understand barriers and facilitators of HCV treatment. More
Unsuccessful Direct-Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort
A study examined characteristics that may indicate an increased probability of unsuccessful DAA HCV treatment. More
Barriers to and Impacts of Hepatitis C Treatment Among People Who Inject Drugs in Kenya: A Qualitative Study
In order for positive treatment outcomes to be sustained, HCV treatment programs must address the barriers patients face at multiple levels and implement system-level changes. More
Community Surveys Show Enthusiasm for Long-Acting HCV Cure Researc
People living with or at risk of hepatitis C virus, health care providers, and policymakers in low- and middle-income countries showed significant interest in a potential long-acting HCV cure, recent surveys have found. More
Immunodeficiency, Injection Drug Use Linked to Failed HCV Treatment in People with HIV
DAAs achieve a 95% success rate in treating HCV among HIV patients, but 5% experience unsuccessful treatment; Lower CD4 cell counts, HCV genotype 4, and recent injection drug use are linked to higher odds of unsuccessful treatment. More
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C - A Survey of Patients
A study explores the challenges and opportunities in long-acting HCV treatment across three LMICs: Egypt, Ethiopia and India. More
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C - A Survey of Providers and Policymakers
A study explores the acceptability and feasibility of long-acting HCV treatment in LMICs by surveying HCV treatment prescribers and policymakers. More
